We will be comparing the differences between NuCana plc (NASDAQ:NCNA) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) as far as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana plc	N/A	0.00	N/A	-0.60	0.00
Paratek Pharmaceuticals Inc.	17.12M	11.70	112.36M	-3.64	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of NuCana plc and Paratek Pharmaceuticals Inc.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of NuCana plc and Paratek Pharmaceuticals Inc.

	Net Margins	Return on Equity	Return on Assets
NuCana plc	0.00%	0%	0%
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%

Liquidity

The Current Ratio and Quick Ratio of NuCana plc are 21.2 and 21.2 respectively. Its competitor Paratek Pharmaceuticals Inc.’s Current Ratio is 11.4 and its Quick Ratio is 11.4. NuCana plc can pay off short and long-term obligations better than Paratek Pharmaceuticals Inc.

Analyst Ratings

NuCana plc and Paratek Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
NuCana plc	0	0	0	0.00
Paratek Pharmaceuticals Inc.	0	0	3	3.00

Competitively the consensus target price of Paratek Pharmaceuticals Inc. is $19, which is potential 207.44% upside.

Insider and Institutional Ownership

The shares of both NuCana plc and Paratek Pharmaceuticals Inc. are owned by institutional investors at 34.6% and 77.7% respectively. Insiders held 15.28% of NuCana plc shares. Comparatively, 3.1% are Paratek Pharmaceuticals Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
NuCana plc	9.97%	-0.46%	-30.08%	-45.98%	-29.7%	-11.03%
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%

For the past year NuCana plc has -11.03% weaker performance while Paratek Pharmaceuticals Inc. has 32.36% stronger performance.

Summary

NuCana plc beats on 6 of the 10 factors Paratek Pharmaceuticals Inc.

NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. The company was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.